Interacting Drugs |
Rilpivirine, emtricitabine, and tenofovir vs Reverse Transcriptase Inhibitors (Non-Nucleoside) |
Security Level |
|
Mechanism |
Reverse Transcriptase Inhibitors (Non-Nucleoside): May increase the serum concentration of Rilpivirine. This mechanism applies to coadministration of delavirdine. Reverse Transcriptase Inhibitors (Non-Nucleoside) may decrease the serum concentration of Rilpivirine. This mechanism applies to coadministration of efavirenz, etravirine, and nevirapine. |
Management |
Avoid combination |
Rilpivirine, emtricitabine, and tenofovir vs Reverse Transcriptase Inhibitors (Non-Nucleoside)
Post Review about Rilpivirine, emtricitabine, and tenofovir vs Reverse Transcriptase Inhibitors (Non-Nucleoside) Click here to cancel reply.
Other Interactions of Rilpivirine, emtricitabine, and tenofovir
Other Interactions of Reverse Transcriptase Inhibitors (Non-Nucleoside)
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.